Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?

European Journal of Cancer

Volumn 51, Issue 8, 2015, Pages 907-914

  Treweek, Shaun ^a   Dryden, Ruth ^b   McCowan, Colin ^c   Harrow, Alison ^d   Thompson, Alastair M ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Institute for Research and Innovation in Social Services   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant treatment; Applicability; Breast cancer; Generalisabilty; Phase III trials; Record linkage

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATIENT PARTICIPATION; PATIENT SELECTION; POPULATION; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PATIENT PARTICIPATION; PATIENT SELECTION; POPULATION; SCOTLAND; TAMOXIFEN;

EID: 84928957523     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.01.064     Document Type: Article

References (37)

1. P.M. Rothwell External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 365 9453 2005 82 93
2. D. Schwartz, and J. Lellouch Explanatory and pragmatic attitudes in therapeutical trials J Chronic Dis 20 1967 637 648
3. S. Treweek, and M. Zwarenstein Making trials matter: pragmatic and explanatory trials and the problem of applicability Trials 10 2009 37
4. J. Travers, S. Marsh, M. Williams, M. Weatherall, B. Caldwell, and P. Shirtcliffe External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 62 2007 219 223
5. J. Travers, S. Marsh, B. Caldwell, M. Williams, S. Aldington, and M. Weatherall External validity of randomized controlled trials in COPD Respir Med 101 2007 1313 1320
6. C. Saunders, C.D. Byrne, B. Guthrie, R.S. Lindsay, J.A. McKnight, and S. Philip External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med 30 3 2013 300 308
7. J. Fraser, N. Steele, A. Al Zaman, and A. Yule Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group Eur J Cancer 47 2011 215 220
8. National Institute for Health and Clinical Excellence The guidelines manual 2009 National Institute for Health and Clinical Excellence London
9. M. Zwarenstein, and S. Treweek What kind of randomized trials do we need? J Clin Epidemiol 62 2009 461 463
10. P.M. Rothwell Factors that can affect the external validity of randomised controlled trials PLoS Clin Trials 1 2006 e9
11. S.R. Tunis, D.B. Stryer, and C.M. Clancy Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy JAMA 290 2003 1624 1632
12. C. McCowan, J. Shearer, P.T. Donnan, J.A. Dewar, M. Crilly, and A.M. Thompson Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 2008 1763 1768
13. C. McCowan, and A.M. Thompson The importance of nonpharmacogenetic factors in endocrine therapy Pharmacogenomics 13 2012 721 728
14. J. Yarnold Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009 Clin Oncol (R Coll Radiol) 21 2009 159 160
15. H.J. Burstein, A.A. Prestrud, J. Seidenfeld, H. Anderson, T.A. Buchholz, and N.E. Davidson American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 23 2010 3784 3796
16. B.D. Smith, S.M. Bentzen, C.R. Correa, C.A. Hahn, P.H. Hardenbergh, and G.S. Ibbott Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline Int J Radiat Oncol Biol Phys 81 1 2011 59 68
17. Scottish Intercollegiate Guidelines Network. SIGN 84 Management of breast cancer in women. A national clinical guideline. Scottish Intercollegiate Guidelines Network. Edinburgh 2005.
18. British Medical Journal. Best Practice: Primary invasive breast cancer. 2012 cited; Available from: < http://bestpractice.bmj.com/best-practice/monograph/716/treatment/step-by-step.html >.
19. B. Makubate, P.T. Donnan, J.A. Dewar, A.M. Thompson, and C. McCowan Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality Br J Cancer 108 2013 1515 1524
20. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
21. A. Fong, J. Shafiq, C. Saunders, A. Thompson, S. Tyldesley, and M.B. Barton A comparison of systemic therapy utilization in British Columbia, Scotland, and Western Australia with models of "optimal" therapy Breast 21 2012 562 569
22. A.T.A.C. The (Arimidex, tamoxifen alone or in combination) trialists' group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial Lancet 359 2002 2131 2139
23. The Breast International Group(BIG) 1-98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
24. T. Whelan, R. MacKenzie, J. Julian, M. Levine, W. Shelley, and L. Grimond Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer J Natl Cancer Inst 94 2002 1143 1150
25. H. Bartelink, J.-C. Horiot, P. Poortmans, H. Struikmans, W. Van den Bogaert, and I. Barillot Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 345 2001 1378 1387
26. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, and T. Delozier A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 2004 1081 1092
27. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, and M.J. Piccart Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802
28. E.P. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S.M. Sedlacek, and B. Fisher Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 2005 3686 3696
29. The START Trialists' Group The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet Oncol 9 2008 331 341
30. The START Trialists' Group The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 371 2008 1098 1107
31. P. Ellis, L.P. Barrett, L. Johnson, D. Cameron, A. Wardley, and S. O'Reilly TACT Trial Management Group; tact trialists. sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomized controlled trial Lancet 373 2009 1681 1692
32. J.S. Vaidya, D.J. Joseph, J.S. Tobias, M. Bulsara, F. Wenz, and C. Saunders Targeted intra-operative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A Trial): an international, prospective, randomized, non-inferiority phase 3 trial Lancet 376 2010 91 102
33. C.J.H. Van de Velde, D. Rea, C. Seynaeve, H. Putter, A. Hasenburg, and J.-M. Vannetzel Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial Lancet 377 2011 321 331
34. A. Howell, J. Cuzick, M. Baum, A. Buzdar, M. Dowsett, and J.F. Forbes ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
35. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA 2007;297:1233-40.
36. C. Mengis, S. Aebi, A. Tobler, W. Dahler, and M.F. Fey Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukemia trials J Clin Oncol 21 2003 3933 3939
37. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, and I. Smith Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672